Who we are
Founded in 1987, Percell Biolytica is one of Sweden’s oldest biotech companies. We specialize in the development, production, and commercialization of CultiSpher® macroporous microcarriers, which are vital in advancing cell-based therapies. Kjell Nilsson, has developed a method to facilitate the production of autologous pharmaceuticals, contributing significantly to our innovative capabilities.
What we do…
We focus on strategic collaborations and agreements that drive our growth and extend our impact in the biotech industry. Notable partnerships include our work with Titan Pharmaceutical Inc. on the production of a proprietary microcarrier for Spheramine™, a cell-based product for treating Parkinson’s disease. We also collaborate with European partners in the European Craft Project, aiming to develop a bio-artificial pancreas for human use.
How we do it…
Our approach involves leveraging advanced research and patented technology to develop innovative biotechnological solutions. For example, Spheramine™ utilizes non-embryonic, human retinal pigment epithelial (RPE) cells adhered to our proprietary microcarrier, allowing for the long-term survival and function of cells implanted in the central nervous system. This technology has demonstrated significant success in both animal studies and clinical trials. Additionally, our CultiSpher microcarriers are produced using a patented process, ensuring a unique and effective product for various medical applications.
Patents
Our patents include the use of CultiSpher with or without cells for both in vivo and in vitro applications.
The new CultiSpher allows the cells to grow in the whole building – 3D scaffold for cell growth.
This picture shows a microcarrier of the old type. The cells can only grow on the surface. When there is no longer any free surface, the cells stop growing.
